Objective: To apprise readers of the ‘state of play’ in the psychiatry of intellectual handicap.
Method: A review was conducted of relevant journals and conference abstracts covering a range of scientific aspects of intellectual disability. Those developments considered to be most significant were summarised. In addition, consideration is given to issues relevant to the politics of disability affecting psychiatric practice in Australia.
Results: There have been considerable developments in our understanding of the pathogenesis of intellectual handicap in pharmacotherapy and the behavioural therapies, in the taxonomy of psychopathology, in epidemiology, in delineation of behaviour phenotypes, and in assessment and measurement of psychopathology.
Conclusion: Intellectual handicap and psychiatry have had a chequered relationship in Australia, but the two fields are now clearly moving again to a closer and more productive collaboration. Recent scientific advances have provided a stimulating environment for this increased activity and interest.
ParmenterT.An analysis of Australian mental health services for people with mental retardation. Australian and New Zealand Journal of Developmental Disorders1988; 14:14–19.
2.
YuSMulleyJLoeschDFragile-X syndrome: unique genetics of the heritable unstable element. American Journal of Human Genetics1992; 50:968–80.
3.
AguilarLCIslasARosiquePPsychometric analysis in children with mental retardation due to perinatal hypoxia treated with fibroblast growth factor (fgf) and showing improvement in mental development. Journal of Intellectual Disability Research1993; 37:507–520.
4.
GunthergentaFBovetPHohlfeldP.Obstetric complications and schizophrenia—a case-control study. British Journal of Psychiatry1994; 164:165–170.
5.
GillbergCColemanM.Autism and medical disorders — a review of the literature. Developmental Medicine and Child Neurology1996; 38:191–202.
6.
FetgussonDMHorwoodLJThe effects of lead levels on the growth of word recognition in middle childhood. International Journal of Epidemiology1993; 22:891–897.
7.
CookEHJr.RowlettRJaselskisCLeventhalBLFluoxetine treatment of children and adults with autistic disorder and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry1992; 31:739–45.
8.
SimpsonGVFoxeJJVaughanHGJrMehtaADSchroederCEIntegration of electrophysiological source analyses, MRI and animal models in the study of visual processing and attention. Electroencephalography and Clinical Neurophysiology1995; 44(Suppl.):76–92.
9.
EinfeldSLGuidelines for the use of psychotropic medication in individuals with developmental disabilities. Australia and New Zealand Journal of Developmental Disabilities1990; 16:71–73.
10.
GunnPBPThe temperament of Down's syndrome toddlers and their siblings. Journal of Child Psychology and Psychiatry and Allied Disciplines1985; 26:973–979.
11.
AmanMSinghNStewartAFieldC.The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency1985; 5:485–491.
12.
EinfeldSLTongeBJThe Developmental Behaviour Checklist: the development and validation of an instrument to assess behavioural and emotional disturbance in children and adolescents with mental retardation. Journal of Autism and Developmental Disorders1995; 25:81–104.
13.
TongeBJDissanyakeCBreretonAVAutism: fifty years on from Kanner. Journal of Paediatrics and Child Health1994; 30:102–107.
14.
MossSGoldbergDPatelPWilkinD.Physical morbidity in older people with moderate, severe and profound mental handicap, and its relation to psychiatric morbidity. Social Psychiatry and Psychiatric Epidemiology1993; 28:32–9.
